LLY - Earnings upcoming, recent news makes this appealingEli Lilly and CompanyBATS:LLYQuantAi-Trendš LLY ā Eli Lilly & Co. Ticker: LLY | Sector: Biotech / Pharmaceuticals Date: July 26, 2025 Current Price: ~$813 Resistance Zone: $825 Support Zone: $740ā$750 š§Ŗ Recent Drug News 1. EMA Backs Alzheimerās Drug Donanemab (Kisunla) The European Medicines Agencyās advisory committee has issued a positive opinion on donanemab for early Alzheimer's patients with confirmed amyloid pathology and fewer ApoE4 gene copies. This reverses a previous rejection and paves the way for a likely EU approval in the coming months. Data from TRAILBLAZERāALZ trials showed slower cognitive decline and improved safety with a modified dosing regimen, while Europeās Alzheimerās patient population is projected to nearly double by 2050. 2. Orforglipron Shows Promising Phase 3 Results Lillyās investigational oral GLPā1 therapy, orforglipron, achieved clinically significant results in Phase 3: A1C reductions of 1.3%ā1.6% across doses, weight loss averaging 7.9% at the highest dose, and efficacy seen as early as four weeks. The safety profile was consistent with injectable GLPā1 drugs, offering a powerful oral option for type 2 diabetes management. ā” Analyst & Market Recap (Past Week) HSBC issued a double downgrade, lowering its rating to "Reduce" and cutting its price target from $1,150 to $700, citing valuation concerns and competitive pressure in the weight-loss space. Erste Group downgraded LLY from āBuyā to āHold,ā slowing expectations around drug pipeline momentum. Despite this, other analysts maintain a positive outlook, with the average 12-month price target in the $1,012ā$1,016 range, spanning a wide band from $700 to $1,190. Investor sentiment is shifting cautiously due to rising competition and high multiples. š Technical & Market Structure Based on the latest 30-minute chart: Price remains stuck within a sideways trading range, bounded by a resistance level near $825 and support in the $740ā$750 area. Momentum is building but hasnāt broken through significant technical thresholds yet. ā Bullish Scenario Trigger: Break and hold above $825 Targets: $850 ā $900 ā $950 Catalysts: Oral GLPā1 approval prospects, Alzheimers regulatory momentum, and possible drug trial successes ā Bearish Scenario Trigger: Breakdown below $740 Targets: $700 ā $670 Risks Include: Rising competition from Novo Nordisk, slowing pipeline news, valuation compression, and analyst downgrades š§ Strategic Summary LLY is operating in a tight technical corridor, with the potential for volatility driven by both clinical and regulatory catalysts. The recent drug developmentsādonanemab's EMA advancement and orforglipron's strong Phase 3 resultsāmay supply fuel for a bullish breakout if momentum shifts convincingly above $825. Conversely, bearish pressure may intensify if the downside at $740 breaks. Key levels to watch: breakout above $825 or failure below $740.